Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 2/2014

01-06-2014 | Skin Cancer (WH Sharfman, Section Editor)

What Is the Role of Chemotherapy in the Treatment of Melanoma?

Authors: Ahmed I. Megahed, MD, Henry B. Koon, MD

Published in: Current Treatment Options in Oncology | Issue 2/2014

Login to get access

Opinion statement

The approval of ipilimumab and inhibitors of the BRAF pathway for the treatment of melanoma has provided multiple therapeutic options for patients. Although these new agents improve survival compared with chemotherapy alone, the majority of patients will progress and will receive chemotherapy at some point in the course of their disease. Whether the clinical efficacy of chemotherapy can be improved by targeting resistance mechanisms is an area of active investigation. In addition, chemotherapy may be of use modulating the efficacy of the newer agents.
Literature
1.
Balch CM et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(36):6199–206.CrossRef
2.
3.
Flaherty KT et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(3):373–9.CrossRef
4.
Hauschild A et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(17):2823–30.CrossRef
5.
Patel PM et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47(10):1476–83.PubMedCrossRef
6.
Atkins MB et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:S11–4.PubMed
7.
Hauschild A et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.PubMedCrossRef
8.
Flaherty KT et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.PubMedCrossRef
9.
10.
11.
12.
Hamid O et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.PubMedCrossRef
13.••
Hofmann MA, et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res. 2011;21(6):516–23. Only randomized trial of comparing chemotherapy to best supportive care in melanoma. Study demonstrates a trend to improved survival in patients treated with chemotherapy.
14.••
Flaherty LE, et al. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. in ASCO Annual Meeting. 2012. Chicago, IL: Journal of Clinical Oncology, 2012 ASCO Annual Meeting Abstracts. Vol 30, No 15_suppl (May 20 Supplement), 2012: 8504. Intergroup trial that demonstrated an improvement in PFS measured in years for biochemotherapy compared to high dose interferon in patients with high risk melanomas. At the time of presentation there was no difference in overall survival.
15.
Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.PubMedCrossRef
16.•
Robert C, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013;14(8):733–40. A randomized phase II study of MEK inhibitor combined with DTIC demonstrated improvement in progression-free survival compared DTIC alone but no improvement in overall survival.
17.
da Rocha Dias S et al. The European Medicines Agency review of vemurafenib (Zelboraf(R)) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2013;49(7):1654–61.PubMedCrossRef
18.•
O’Day SJ, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211–8. Randomized phase III study suggested the combination of elesclomol plus paclitaxel may decrease survival in some patient subgroups.
19.
Kim KB et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(1):34–41.CrossRef
20.••
Society for Melanoma Research 2012 Congress. Pigment Cell Melanoma Res. 2012;25(6):836–903. Phase III study that demonstrates improved PFS of nab-paclitaxel compared to DTIC monotherapy. There was a trend to improved overall survival that was not statistically significant.
21.
Atkins MB et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(35):5748–54.CrossRef
22.
Keilholz U et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(27):6747–55.CrossRef
23.
Tsang LL et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27(5):342–6.PubMedCrossRef
24.
25.
Middleton MR et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(1):158–66.
26.
Micromedex® Healthcare Series [Intranet database] Thomson Healthcare, Greenwood Village, CO.
27.
Hersh EM et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010;116(1):155–63.PubMed
28.
Bedikian AY et al. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14(1):63–6.PubMedCrossRef
29.
Einzig AI et al. A phase II study of taxol in patients with malignant melanoma. Investig New Drugs. 1991;9(1):59–64.CrossRef
30.
Walker L et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res. 2005;15(5):453–9.PubMedCrossRef
31.
Kloover JS et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90(2):304–5.PubMedCentralPubMedCrossRef
32.
Desai N et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(4):1317–24.CrossRef
33.
Ibrahim NK et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(5):1038–44.
34.
Hodi FS et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25(3):283–6.PubMedCrossRef
35.
Zimpfer-Rechner C et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13(5):531–6.PubMedCrossRef
36.
Rosenberg SA et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(3):968–75.
37.
Eton O et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(8):2045–52.CrossRef
38.
Bajetta E et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2006;17(4):571–7.CrossRef
39.
Ridolfi R et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(6):1600–7.CrossRef
40.
Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(2):328–31.CrossRef
41.
Rietschel P et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(14):2299–304.CrossRef
42.
Ranson M et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(18):2540–5.CrossRef
43.
Hassel JC et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer. 2010;103(6):820–6.PubMedCentralPubMedCrossRef
44.
Busch C et al. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer. 2010;46(11):2127–33.PubMedCrossRef
45.
Middleton MR et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer. 1998;78(9):1199–202.PubMedCentralPubMedCrossRef
46.
Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs. 2004;5(6):623–7.PubMed
47.
Plummer R et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer chemother Pharmacol. 2013;71(5):1191–9.PubMedCrossRef
48.
49.
O’Day S, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27(32):5452–8.
50.
Haass NK et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(1):230–9.CrossRef
51.••
Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. Report that demonstrates the importance of CRT expression in chemotherapy induced immunogenic cell death.
52.
Tesniere A et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–91.PubMedCrossRef
53.
54.
Obeid M et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14(10):1848–50.PubMedCrossRef
55.
Panaretakis T et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;15(9):1499–509.PubMedCrossRef
56.
Cao C et al. Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cell Mol Immunol. 2009;6(6):469–75.PubMedCrossRef
57.
Nair S et al. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol. 1999;162(11):6426–32.PubMed
58.
Teimouri F, Nikfar S, Abdollahi M. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res. 2013.
59.
Schwarzberg AB et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Investig. 2007;25(4):249–55.CrossRef
60.
Muranski P et al. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nature clinical practice. Oncology. 2006;3(12):668–81.PubMedCentralPubMed
61.
Dudley ME et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(32):5233–9.CrossRef
62.
Laurent J et al. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother. 2010;33(7):723–34.PubMedCrossRef
63.
Gunturu KS et al. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(7):1196–202.CrossRef
64.
Appay V et al. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother. 2007;30(2):240–50.PubMedCrossRef
65.
Powell Jr DJ et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol. 2006;177(9):6527–39.PubMedCentralPubMedCrossRef
66.
Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988;48(6):1671–5.PubMed
67.
Ge Y et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012;61(3):353–62.PubMedCrossRef
68.
Heylmann D et al. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. PLoS ONE. 2013;8(12):e83384.PubMedCentralPubMedCrossRef
69.
Verdi CJ et al. Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer. J Immunother Off J Soc Biol Ther. 1992;11(4):286–91.CrossRef
70.
Lindemann A et al. A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies. Cancer Treat Rev. 1989;16 Suppl A:53–7.PubMedCrossRef
71.
Wadler S et al. Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am J Clin Oncol. 1988;11(1):55–9.PubMedCrossRef
72.
Camisaschi C et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother. 2013;62(5):897–908.PubMedCentralPubMedCrossRef
73.
Vincent J et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–61.PubMedCrossRef
74.
Suzuki E et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(18):6713–21.CrossRef
75.
Annels NE, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother. 2013.
76.
Lesterhuis WJ et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE. 2013;8(4):e61895.PubMedCentralPubMedCrossRef
77.
Reck M et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2013;24(1):75–83.CrossRef
78.
Lynch TJ et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(17):2046–54.CrossRef
79.
O'Day, S.J., et al., Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. 27(36): p. 6207--12.ttrack
Metadata
Title
What Is the Role of Chemotherapy in the Treatment of Melanoma?
Authors
Ahmed I. Megahed, MD
Henry B. Koon, MD
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 2/2014
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-014-0277-5

Other articles of this Issue 2/2014

Current Treatment Options in Oncology 2/2014 Go to the issue

Lymphoma (A Engert, Section Editor)

Radiotherapy of Follicular Lymphoma: Updated Role and New Rules

Skin Cancer (WH Sharfman, Section Editor)

Update on Vaccines for High-Risk Melanoma

Lymphoma (A Engert, Section Editor)

The Role of Allogeneic Stem Cell Transplantation in Hodgkin’s Lymphoma

Lymphoma (A Engert, Section Editor)

Ibrutinib in B-cell Lymphomas

Leukemia (JP Dutcher, Section Editor)

Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission

Lymphoma (A Engert, Section Editor)

Role of PET in Lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits